Phase 2 Start

LSTA: Phase 2 Start: A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Int

Name: Phase 2 Start: A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Int
Start: 2030-01-01
End: 2030-01-01

January 1, 2030. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: January 1, 2030
Company: LISATA THERAPEUTICS, INC. (LSTA)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 2 Start~month

Phase 2 Start: A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Int

January 1, 2030

LSTA overview →

Company: LISATA THERAPEUTICS, INC. (LSTA)
Indication: PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Cancer